GO:0010902 positive regulation of very-low-density lipoprotein particle remodeling: Lipid Metabolism Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010902 describes any process that increases the rate, frequency, or extent of very-low-density lipoprotein (VLDL) particle remodeling, a key step in triglyceride-rich lipoprotein metabolism.
• VLDL remodeling involves the hydrolysis of triglycerides by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acids, as well as the acquisition, loss, or modification of proteins and lipids within the particle.
• Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma, linking VLDL remodeling to overall lipoprotein homeostasis.
• Genetic and dietary factors, including sulfur microbial diet and smoking, interact with polygenic variants associated with lipoprotein metabolism, influencing VLDL remodeling.
• Dysregulation of VLDL remodeling is implicated in cardiovascular diseases such as myocardial infarction, as supported by biomarker and Mendelian randomization studies.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal interrogation of genes regulating VLDL remodeling for therapeutic target discovery.
Description
Very-low-density lipoprotein (VLDL) particles are triglyceride-rich lipoproteins secreted by the liver that undergo remodeling in the circulation, a process critical for lipid transport and energy distribution. GO:0010902, positive regulation of very-low-density lipoprotein particle remodeling, encompasses any process that increases the rate, frequency, or extent of VLDL remodeling, including the hydrolysis of triglycerides by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acids. This term is essential for researchers studying lipid metabolism because VLDL remodeling directly impacts plasma triglyceride levels, cholesterol esterification, and HDL remodeling, all of which are linked to cardiometabolic risk. Understanding the positive regulation of VLDL remodeling provides mechanistic insights into dyslipidemia, atherosclerosis, and myocardial infarction. Moreover, genetic and environmental factors, such as polygenic variants and dietary components, modulate this process, highlighting its complexity and therapeutic potential.
positive regulation of very-low-density lipoprotein particle remodeling At A Glance
| GO ID | GO:0010902 |
|---|---|
| GO term | positive regulation of very-low-density lipoprotein particle remodeling |
| Ontology | biological_process |
| Synonym | positive regulation of very-low-density lipoprotein particle remodelling; positive regulation of VLDL remodeling; positive regulation of VLDL remodelling |
| Major function | Increases the rate, frequency, or extent of VLDL particle remodeling, including triglyceride hydrolysis and free fatty acid loss. |
| Related process | VLDL particle remodeling (GO:0034370) and lipoprotein metabolism. |
| Key enzymes | Hepatic lipase (LIPC), lipoprotein lipase (LPL), and other lipases. |
| Physiological context | Plasma lipid transport, triglyceride metabolism, and cholesterol esterification/transfer. |
What Is GO:0010902?
GO:0010902 is a biological process term defined as any process that increases the rate, frequency, or extent of very-low-density lipoprotein particle remodeling. VLDL particle remodeling itself refers to the acquisition, loss, or modification of a protein or lipid within a VLDL particle, including the hydrolysis of triglyceride by hepatic lipase or lipoprotein lipase and the subsequent loss of free fatty acid. In essence, it covers the regulatory mechanisms that enhance the structural and compositional changes of VLDL particles in the bloodstream.
Why Is positive regulation of very-low-density lipoprotein particle remodeling Important in Cell Biology?
Positive regulation of VLDL remodeling is crucial because it directly controls plasma triglyceride levels and influences the composition and function of other lipoproteins, such as HDL. Dysregulation of this process contributes to hypertriglyceridemia, atherosclerosis, and increased risk of myocardial infarction. Furthermore, genetic and dietary factors that modulate VLDL remodeling can alter cardiovascular disease susceptibility, making this pathway a prime target for therapeutic intervention and biomarker discovery.
• Controls plasma triglyceride clearance and fatty acid delivery to tissues.
• Influences cholesterol esterification and HDL remodeling, affecting reverse cholesterol transport.
• Modulated by genetic variants associated with lipoprotein metabolism, impacting personalized risk.
• Interacts with dietary factors such as sulfur microbial diet and smoking status.
• Dysregulation is linked to myocardial infarction and other cardiovascular diseases.
• Serves as a target for lipid-lowering therapies and drug development.
• Provides mechanistic insights into metabolic syndrome and insulin resistance.
• Enables study of gene-environment interactions in dyslipidemia.
• Facilitates biomarker discovery for cardiovascular risk stratification.
• Supports CRISPR-based functional genomics to identify causal genes.
What Happens During positive regulation of very-low-density lipoprotein particle remodeling?
Triglyceride Hydrolysis by Lipases
In simple terms: Enzymes break down fats inside VLDL particles, shrinking them.
The primary step in VLDL remodeling is the hydrolysis of triglycerides by hepatic lipase (LIPC) or lipoprotein lipase (LPL), which releases free fatty acids for tissue uptake. Positive regulation of this step increases the rate of triglyceride breakdown, leading to smaller, denser VLDL remnants and enhanced clearance from circulation.
Loss of Free Fatty Acids and Particle Shrinkage
In simple terms: After fats are broken down, the fatty acids leave the particle, making it smaller.
Following hydrolysis, free fatty acids are lost from the VLDL particle, reducing its core lipid content and altering its surface composition. This loss is a key remodeling event that facilitates the conversion of VLDL to intermediate-density lipoprotein (IDL) and eventually LDL.
Modification of Apolipoproteins and Surface Lipids
In simple terms: Proteins on the particle surface change, affecting how it interacts with other lipoproteins.
VLDL remodeling also involves the acquisition, loss, or modification of proteins such as apolipoproteins (e.g., APOE, APOC) and surface lipids. These changes influence receptor binding, enzyme activity, and the transfer of lipids between lipoproteins, including cholesterol ester transfer protein (CETP)-mediated exchange.
Impact on Cholesterol Esterification and HDL Remodeling
In simple terms: The breakdown of VLDL fats affects cholesterol processing and HDL particles.
Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Positive regulation of VLDL remodeling thus indirectly modulates HDL composition and function, affecting reverse cholesterol transport and overall lipid homeostasis.
Key Genes Involved in GO:0010902 positive regulation of very-low-density lipoprotein particle remodeling
The following genes and proteins are central to the positive regulation of VLDL particle remodeling, based on their established roles in lipid metabolism and lipoprotein processing.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LPL | Lipoprotein lipase; hydrolyzes triglycerides in VLDL | Rate-limiting enzyme for VLDL remodeling; target for hypertriglyceridemia |
| LIPC | Hepatic lipase; hydrolyzes triglycerides and phospholipids in VLDL remnants | Modulates VLDL and HDL remodeling; linked to hepatic lipase deficiency |
| APOE | Apolipoprotein E; mediates VLDL clearance via receptor binding | Isoform-specific effects on VLDL remodeling and cardiovascular risk |
| APOC3 | Apolipoprotein C-III; inhibits LPL and hepatic lipase | Inhibitor of VLDL remodeling; target for antisense therapies |
| APOB | Apolipoprotein B; structural component of VLDL | Required for VLDL assembly and secretion; mutations cause hypobetalipoproteinemia |
| CETP | Cholesteryl ester transfer protein; transfers lipids between VLDL and HDL | Modulates VLDL remodeling and HDL composition; drug target |
| PLTP | Phospholipid transfer protein; transfers phospholipids to VLDL | Influences VLDL surface remodeling and HDL metabolism |
| ANGPTL3 | Inhibits LPL activity | Regulator of VLDL remodeling; target for lipid-lowering drugs |
| ANGPTL4 | Inhibits LPL activity | Modulates VLDL remodeling in response to fasting |
| APOA5 | Activates LPL and enhances VLDL hydrolysis | Genetic variants affect triglyceride levels and VLDL remodeling |
| GPIHBP1 | Endothelial protein that anchors LPL | Essential for LPL-mediated VLDL remodeling |
| LMF1 | Lipase maturation factor 1; required for LPL and hepatic lipase folding | Mutations cause combined lipase deficiency |
| SEL1L | ER protein involved in lipase maturation | Supports LPL and hepatic lipase secretion |
| CREB3L3 | Transcription factor regulating lipase expression | Controls VLDL remodeling gene programs |
| NR1H2 | LXR beta; regulates lipid metabolism genes | Modulates VLDL remodeling via transcriptional control |
| PPARA | Peroxisome proliferator-activated receptor alpha; regulates LPL and APOA5 | Fibrate target; enhances VLDL remodeling |
| INSIG1 | Regulates SREBP processing and lipogenesis | Indirectly affects VLDL secretion and remodeling |
| MTTP | Microsomal triglyceride transfer protein; required for VLDL assembly | Mutations cause abetalipoproteinemia; impacts VLDL availability |
How Is positive regulation of very-low-density lipoprotein particle remodeling Regulated?
The positive regulation of VLDL particle remodeling is controlled at multiple levels, including transcriptional regulation of lipases and apolipoproteins by nuclear receptors such as PPARA and NR1H2, and post-translational modulation by ANGPTL3, ANGPTL4, and APOC3. Additionally, genetic variants associated with lipoprotein metabolism interact with dietary factors and smoking status, further influencing VLDL remodeling. Triglyceride levels themselves are major determinants of cholesterol esterification/transfer and HDL remodeling, creating a feedback loop that regulates overall lipoprotein homeostasis.
positive regulation of very-low-density lipoprotein particle remodeling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LPL | Hypertriglyceridemia, atherosclerosis | Knockout mouse, point mutation knock-in |
| APOC3 | Hypertriglyceridemia, cardiovascular disease | Overexpression, knockout |
| ANGPTL3 | Familial combined hypolipidemia | Knockout, point mutation |
| APOA5 | Hypertriglyceridemia | Knock-in, knockout |
| CETP | Dyslipidemia, cardiovascular risk | Overexpression, knockout |
Cardiovascular Disease and Myocardial Infarction
Dysregulation of VLDL remodeling leads to elevated triglycerides and remnant cholesterol, which are causal risk factors for myocardial infarction. Biomarker and Mendelian randomization studies have identified blood and urine biomarkers linked to myocardial infarction, underscoring the clinical relevance of VLDL remodeling pathways.
Hypertriglyceridemia and Metabolic Syndrome
Impaired positive regulation of VLDL remodeling results in hypertriglyceridemia, a hallmark of metabolic syndrome. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling, so their accumulation disrupts overall lipid homeostasis.
Gene-Environment Interactions in Dyslipidemia
Polygenic variants associated with lipoprotein metabolism interact with energy and sulfur microbial diet and smoking status, modulating VLDL remodeling and influencing dyslipidemia risk. This highlights the importance of considering both genetic and environmental factors in disease prevention.
From positive regulation of very-low-density lipoprotein particle remodeling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LPL affect VLDL remodeling rate? | LPL knockout cell line (e.g., HepG2) |
| Does APOC3 point mutation alter LPL inhibition? | Point mutation knock-in in hepatocytes |
| Can APOA5 overexpression enhance VLDL hydrolysis? | Overexpression in Huh7 cells |
| Does ANGPTL3 knockout increase VLDL remodeling? | Knockout in primary hepatocytes |
| Does CETP knock-in in mice mimic human VLDL remodeling? | Knock-in mouse model |
| Can tagged LIPC track VLDL remodeling dynamics? | Tagged knock-in (e.g., GFP-LIPC) |
How to Study the positive regulation of very-low-density lipoprotein particle remodeling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS) | Triglyceride and free fatty acid species | Quantify VLDL remodeling products |
| NMR lipoprotein profiling | VLDL particle size and concentration | Assess remodeling in clinical samples |
| Lipase activity assay | Hydrolysis rate of triglycerides | Screen for LPL or hepatic lipase modulators |
| CRISPR knockout screen | Gene essentiality for VLDL remodeling | Identify novel regulators |
| RNA-seq | Transcriptional changes in lipid genes | Evaluate regulatory networks |
| Proteomics | Protein composition of VLDL particles | Detect apolipoprotein modifications |
| Western blot | Protein expression of LPL, APOC3, etc. | Validate CRISPR models |
| Mendelian randomization | Causal effect of biomarkers on disease | Link VLDL remodeling to myocardial infarction |
Lipidomic and Lipoprotein Profiling
Mass spectrometry-based lipidomics and NMR lipoprotein profiling quantify changes in VLDL particle size, triglyceride content, and free fatty acid release, directly measuring remodeling.
Enzyme Activity Assays
Lipase activity assays (LPL, hepatic lipase) using radiolabeled or fluorescent triglyceride substrates assess the hydrolysis step of VLDL remodeling.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens in hepatocyte cell lines identify positive regulators of VLDL remodeling, followed by validation with targeted knockouts.
Transcriptomics and Proteomics
RNA-seq and proteomics reveal expression changes in lipases, apolipoproteins, and regulators under conditions that modulate VLDL remodeling, providing mechanistic insights.
How CRISPR Can Be Used to Study GO:0010902 positive regulation of very-low-density lipoprotein particle remodeling
Knockout
CRISPR knockout of genes such as LPL, APOC3, or ANGPTL3 in hepatocyte cell lines or animal models abolishes their function, allowing researchers to measure the impact on VLDL remodeling rate and lipid profiles.
Point Mutation
Introducing disease-associated point mutations (e.g., in APOA5 or LPL) via CRISPR base editing or HDR recreates human genetic variants, enabling study of their effects on VLDL remodeling and drug response.
Knock-in
Knock-in of tagged versions of LIPC or LPL (e.g., GFP or HA tags) allows real-time tracking of enzyme localization and dynamics during VLDL remodeling in live cells.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of positive regulators such as APOA5 or LPL enhances VLDL remodeling, providing gain-of-function models to test therapeutic hypotheses.
How EDITGENE Supports positive regulation of very-low-density lipoprotein particle remodeling Research
Researchers studying positive regulation of very-low-density lipoprotein particle remodeling-related genes often need to determine whether a candidate gene is causally involved in this process or merely correlated. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes identified from genomic or screening studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of very-low-density lipoprotein particle remodeling research.
Frequently Asked Questions About positive regulation of very-low-density lipoprotein particle remodeling
What is GO:0010902?
GO:0010902 is a Gene Ontology biological process term for any process that increases the rate, frequency, or extent of very-low-density lipoprotein particle remodeling, including triglyceride hydrolysis and free fatty acid loss.
What genes are involved in positive regulation of VLDL remodeling?
Key genes include LPL, LIPC, APOE, APOC3, APOB, CETP, ANGPTL3, APOA5, and GPIHBP1, among others.
How is VLDL remodeling regulated?
It is regulated by lipases, apolipoproteins, ANGPTL proteins, and nuclear receptors, with genetic and dietary factors influencing the process.
What diseases are associated with VLDL remodeling?
Dysregulation is linked to hypertriglyceridemia, metabolic syndrome, atherosclerosis, and myocardial infarction.
What methods study VLDL remodeling?
Lipidomics, lipase activity assays, CRISPR screens, RNA-seq, and proteomics are commonly used.
Can CRISPR be used to study VLDL remodeling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable functional interrogation of genes regulating VLDL remodeling.
What is the role of triglycerides in VLDL remodeling?
Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling, and their hydrolysis is central to VLDL remodeling.
How does diet affect VLDL remodeling?
Energy and sulfur microbial diet interact with polygenic variants to modulate lipoprotein metabolism, including VLDL remodeling.
What biomarkers indicate VLDL remodeling?
Blood and urine biomarkers linked to myocardial infarction can reflect VLDL remodeling activity.
Why is positive regulation of VLDL remodeling important?
It controls plasma triglyceride clearance and influences cardiovascular disease risk, making it a therapeutic target.
Conclusion
GO:0010902, positive regulation of very-low-density lipoprotein particle remodeling, is a critical biological process that governs triglyceride-rich lipoprotein metabolism and impacts cardiovascular health. Understanding its molecular players and regulatory mechanisms offers opportunities for therapeutic intervention in dyslipidemia and myocardial infarction. CRISPR-based models and advanced omics technologies are indispensable for dissecting this pathway and identifying novel drug targets.
References
- 1. Hur HJ et al.. 2023. Interaction of energy and sulfur microbial diet and smoking status with polygenic variants associated with lipoprotein metabolism.. Front Nutr 10:1244185 PMID: 37860035
- 2. Murakami T et al.. 1995. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma.. Arterioscler Thromb Vasc Biol 15(11):1819-28 PMID: 7583561
- 3. Ding Y et al.. 2025. Blood and urine biomarkers and myocardial infarction: A 2-sample and multivariate combination of Mendelian randomization.. Medicine (Baltimore) 104(49):e46146 PMID: 41366970
